0001661181-18-000035.txt : 20181212
0001661181-18-000035.hdr.sgml : 20181212
20181212194611
ACCESSION NUMBER: 0001661181-18-000035
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181210
FILED AS OF DATE: 20181212
DATE AS OF CHANGE: 20181212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bilbo Patrick
CENTRAL INDEX KEY: 0001759203
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37906
FILM NUMBER: 181231893
MAIL ADDRESS:
STREET 1: C/O ORGANOGENESIS INC.
STREET 2: 85 DAN ROAD
CITY: CANTON
STATE: MA
ZIP: 02021
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Organogenesis Holdings Inc.
CENTRAL INDEX KEY: 0001661181
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 85 DAN ROAD
CITY: CANTON
STATE: MA
ZIP: 02021
BUSINESS PHONE: 781-575-0775
MAIL ADDRESS:
STREET 1: 85 DAN ROAD
CITY: CANTON
STATE: MA
ZIP: 02021
FORMER COMPANY:
FORMER CONFORMED NAME: Avista Healthcare Public Acquisition Corp.
DATE OF NAME CHANGE: 20151215
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2018-12-10
0001661181
Organogenesis Holdings Inc.
ORGO
0001759203
Bilbo Patrick
C/O ORGANOGENESIS HOLDINGS INC.
85 DAN ROAD
CANTON
MA
02021
0
1
0
0
Chief Operating Officer
Common Stock
2018-12-10
4
A
0
121800
A
121800
D
Stock Option (Right to Buy)
1.44
2018-12-10
4
A
0
30450
A
2021-12-06
Common Stock
30450
30450
D
Stock Option (Right to Buy)
1.18
2018-12-10
4
A
0
152250
A
2024-04-10
Common Stock
152250
152250
D
Stock Option (Right to Buy)
3.46
2018-12-10
4
A
0
142100
A
2027-05-04
Common Stock
142100
142100
D
Stock Option (Right to Buy)
3.46
2018-12-10
4
A
0
101500
A
2027-05-04
Common Stock
101500
101500
D
Received in connection with the Issuer's business combination (the "Merger") with Organogenesis Inc. ("Organogenesis") in accordance with the terms of the Agreement and Plan of Merger dated as of August 17, 2018 among the Issuer, which was then referred to as Avista Healthcare Public Acquisition Corp., Avista Healthcare Merger Sub, Inc. and Organogenesis, in exchange for 60,000 shares of common stock of Organogenesis.
100% of the shares subject to this option are fully vested and exercisable.
Received in connection with the Merger in exchange for an option to acquire 15,000 shares of common stock of Organogenesis for $2.92 per share.
The shares underlying the option vested or shall vest 20% annually beginning on January 1, 2015.
Received in connection with the Merger in exchange for an option to acquire 75,000 shares of common stock of Organogenesis for $2.38 per share.
The shares underlying the option vested or shall vest 20% annually beginning on December 31, 2017.
Received in connection with the Merger in exchange for an option to acquire 70,000 shares of common stock of Organogenesis for $7.01 per share.
The shares underlying the option vested or shall vest 20% annually beginning on January 1, 2018.
Received in connection with the Merger in exchange for an option to acquire 50,000 shares of common stock of Organogenesis for $7.01 per share.
/s/ Stacie S. Aarestad, Attorney-in-Fact
2018-12-12